Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Apr 12, 2018

SOUTH PLAINFIELD, N.J. , April 12, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its common stock, which closed on April 3, 2018 , have exercised in full their option to purchase

Additional Formats
Apr 09, 2018

SOUTH PLAINFIELD, N.J. , April 9, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York City . Members of PTC's senior management and research teams will provide a corporate update

Additional Formats
Apr 04, 2018

SOUTH PLAINFIELD, N.J. , April 4, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC's Huntington's disease program. The program is optimizing small-molecule compounds—identified using PTC's

Additional Formats
Mar 27, 2018

SOUTH PLAINFIELD, N.J. , March 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underwriters an option for

Additional Formats
Mar 19, 2018
SOUTH PLAINFIELD, N.J. , March 19, 2018 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on March 13 , 2018 it approved non-statutory stock options to purchase an aggregate of 25,200 shares of its common stock to six new employees.
Additional Formats
Mar 15, 2018
- First patient dosed in Type 1 Spinal Muscular Atrophy Program - SOUTH PLAINFIELD, N.J. , March 15, 2018 /PRNewswire/ --   PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that the FIREFISH study of RG7916 in Type 1 spinal muscular atrophy (SMA) patients has transitioned into its pivotal
Additional Formats
Mar 06, 2018
- 2017 total revenues of $194M, a 135% increase vs. 2016 -
- Full year 2018 net product revenue guidance of $260M to $295M -
- Conference call at 4:30 p.m. ET -
Additional Formats
Mar 01, 2018
SOUTH PLAINFIELD, N.J. , March 1, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 38 th Annual Health Care Conference , on Wednesday, March 14th at 8:00 a.m.
Additional Formats
Feb 28, 2018
SOUTH PLAINFIELD, N.J. , Feb. 28, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on February 26, 2018 it approved non-statutory stock options to purchase an aggregate of 96,750 shares of its common stock to sixteen new employees.
Additional Formats
Feb 21, 2018
SOUTH PLAINFIELD, N.J. , Feb. 21, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2017 financial results and provide an update on the company's business and outlook on Tuesday,
Additional Formats